{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T17:45:26Z","timestamp":1792431926224,"version":"4.5.0"},"reference-count":52,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2025,2,12]],"date-time":"2025-02-12T00:00:00Z","timestamp":1739318400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,2,12]],"date-time":"2025-02-12T00:00:00Z","timestamp":1739318400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100000289","name":"Cancer Research UK","doi-asserted-by":"publisher","award":["DRCRPG-Nov21\\100001"],"award-info":[{"award-number":["DRCRPG-Nov21\\100001"]}],"id":[{"id":"10.13039\/501100000289","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Oncogene"],"published-print":{"date-parts":[[2025,3,17]]},"DOI":"10.1038\/s41388-024-03265-0","type":"journal-article","created":{"date-parts":[[2025,2,12]],"date-time":"2025-02-12T10:07:56Z","timestamp":1739354876000},"page":"618-629","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":16,"title":["PPP2R1A mutations cause ATR inhibitor sensitivity in ovarian clear cell carcinoma"],"prefix":"10.1038","volume":"44","author":[{"given":"James","family":"Stewart","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4298-7272","authenticated-orcid":false,"given":"Dragomir B.","family":"Krastev","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachel","family":"Brough","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diana","family":"Zatreanu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Feifei","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph S.","family":"Baxter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandhya","family":"Sridhar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jessica","family":"Frankum","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Asha","family":"Konde","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6398-4508","authenticated-orcid":false,"given":"William","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6685-5480","authenticated-orcid":false,"given":"Syed","family":"Haider","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Alexander","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kai","family":"Betteridge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aditi","family":"Gulati","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ayoma D.","family":"Attygalle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katherine","family":"Vroobel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9987-2946","authenticated-orcid":false,"given":"Rachael","family":"Natrajan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saira","family":"Khalique","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3354-5643","authenticated-orcid":false,"given":"Theodoros I.","family":"Roumeliotis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0881-5477","authenticated-orcid":false,"given":"Jyoti S.","family":"Choudhary","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2415-4824","authenticated-orcid":false,"given":"Jason","family":"Yeung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9307-3262","authenticated-orcid":false,"given":"Andrew J.","family":"Wicks","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rebecca","family":"Marlow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susana","family":"Banerjee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3313-3857","authenticated-orcid":false,"given":"Stephen J.","family":"Pettitt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8715-2901","authenticated-orcid":false,"given":"Andrew N. J.","family":"Tutt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3226-0515","authenticated-orcid":false,"given":"Christopher J.","family":"Lord","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,2,12]]},"reference":[{"key":"3265_CR1","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1016\/j.ygyno.2008.02.006","volume":"109","author":"JK Chan","year":"2008","unstructured":"Chan JK, Teoh D, Hu JM, Shin JY, Osann K, Kapp DS. Do clear cell ovarian carcinomas have poorer prognosis compared to other epithelial cell types? A study of 1411 clear cell ovarian cancers. Gynecol Oncol. 2008;109:370\u20136.","journal-title":"Gynecol Oncol"},{"key":"3265_CR2","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1136\/jcp.2007.049478","volume":"61","author":"WG McCluggage","year":"2008","unstructured":"McCluggage WG. My approach to and thoughts on the typing of ovarian carcinomas. J Clin Pathol. 2008;61:152\u201363.","journal-title":"J Clin Pathol"},{"key":"3265_CR3","doi-asserted-by":"crossref","first-page":"S20","DOI":"10.1097\/IGC.0000000000000289","volume":"24","author":"A Okamoto","year":"2014","unstructured":"Okamoto A, Glasspool RM, Mabuchi S, Matsumura N, Nomura H, Itamochi H, et al. Gynecologic Cancer InterGroup (GCIG) consensus review for clear cell carcinoma of the ovary. Int J Gynecol Cancer. 2014;24:S20\u201325.","journal-title":"Int J Gynecol Cancer"},{"key":"3265_CR4","first-page":"432","volume":"15","author":"S Pather","year":"2005","unstructured":"Pather S, Quinn MA. Clear-cell cancer of the ovary-is it chemosensitive? Int J Gynecol Cancer. 2005;15:432\u20137.","journal-title":"Int J Gynecol Cancer"},{"key":"3265_CR5","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1111\/j.1525-1438.2007.01158.x","volume":"18","author":"M Takano","year":"2008","unstructured":"Takano M, Sugiyama T, Yaegashi N, Sakuma M, Suzuki M, Saga Y, et al. Low response rate of second-line chemotherapy for recurrent or refractory clear cell carcinoma of the ovary: a retrospective Japan Clear Cell Carcinoma Study. Int J Gynecol Cancer. 2008;18:937\u201342.","journal-title":"Int J Gynecol Cancer"},{"key":"3265_CR6","doi-asserted-by":"crossref","first-page":"283","DOI":"10.5694\/mja14.00132","volume":"201","author":"S Anuradha","year":"2014","unstructured":"Anuradha S, Webb PM, Blomfield P, Brand AH, Friedlander M, Leung Y, et al. Survival of Australian women with invasive epithelial ovarian cancer: a population-based study. Med J Aust. 2014;201:283\u20138.","journal-title":"Med J Aust"},{"key":"3265_CR7","doi-asserted-by":"crossref","first-page":"e232","DOI":"10.1371\/journal.pmed.0050232","volume":"5","author":"M Kobel","year":"2008","unstructured":"Kobel M, Kalloger SE, Boyd N, McKinney S, Mehl E, Palmer C, et al. Ovarian carcinoma subtypes are different diseases: implications for biomarker studies. PLoS Med. 2008;5:e232.","journal-title":"PLoS Med"},{"key":"3265_CR8","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1126\/science.1196333","volume":"330","author":"S Jones","year":"2010","unstructured":"Jones S, Wang TL, Shih IM, Mao TL, Nakayama K, Roden R, et al. Frequent mutations of chromatin remodeling gene ARID1A in ovarian clear cell carcinoma. Science. 2010;330:228\u201331.","journal-title":"Science"},{"key":"3265_CR9","doi-asserted-by":"crossref","first-page":"1597","DOI":"10.2353\/ajpath.2009.081000","volume":"174","author":"KT Kuo","year":"2009","unstructured":"Kuo KT, Mao TL, Jones S, Veras E, Ayhan A, Wang TL, et al. Frequent activating mutations of PIK3CA in ovarian clear cell carcinoma. Am J Pathol. 2009;174:1597\u2013601.","journal-title":"Am J Pathol"},{"key":"3265_CR10","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1002\/path.2911","volume":"224","author":"KC Wiegand","year":"2011","unstructured":"Wiegand KC, Lee AF, Al-Agha OM, Chow C, Kalloger SE, Scott DW, et al. Loss of BAF250a (ARID1A) is frequent in high-grade endometrial carcinomas. J Pathol. 2011;224:328\u201333.","journal-title":"J Pathol"},{"key":"3265_CR11","doi-asserted-by":"crossref","first-page":"1521","DOI":"10.1158\/1078-0432.CCR-10-1688","volume":"17","author":"DS Tan","year":"2011","unstructured":"Tan DS, Iravani M, McCluggage WG, Lambros MB, Milanezi F, Mackay A, et al. Genomic analysis reveals the molecular heterogeneity of ovarian clear cell carcinomas. Clin Cancer Res. 2011;17:1521\u201334.","journal-title":"Clin Cancer Res"},{"key":"3265_CR12","doi-asserted-by":"crossref","first-page":"1442","DOI":"10.1016\/j.ajpath.2011.01.009","volume":"178","author":"IeM Shih","year":"2011","unstructured":"Shih IeM, Panuganti PK, Kuo KT, Mao TL, Kuhn E, Jones S, et al. Somatic mutations of PPP2R1A in ovarian and uterine carcinomas. Am J Pathol. 2011;178:1442\u20137.","journal-title":"Am J Pathol"},{"key":"3265_CR13","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1002\/path.4315","volume":"232","author":"RC Wu","year":"2014","unstructured":"Wu RC, Ayhan A, Maeda D, Kim KR, Clarke BA, Shaw P, et al. Frequent somatic mutations of the telomerase reverse transcriptase promoter in ovarian clear cell carcinoma but not in other major types of gynaecological malignancy. J Pathol. 2014;232:473\u201381.","journal-title":"J Pathol"},{"key":"3265_CR14","doi-asserted-by":"crossref","first-page":"5242","DOI":"10.3390\/cancers13205242","volume":"13","author":"D Oliveira","year":"2021","unstructured":"Oliveira D, Schnack TH, Poulsen TS, Christiansen AP, Hogdall CK, Hogdall EV. Genomic Sub-Classification of Ovarian Clear Cell Carcinoma Revealed by Distinct Mutational Signatures. Cancers. 2021;13:5242.","journal-title":"Cancers"},{"key":"3265_CR15","volume":"7","author":"CT Williamson","year":"2016","unstructured":"Williamson CT, Miller R, Pemberton HN, Jones SE, Campbell J, Konde A, et al. ATR inhibitors as a synthetic lethal therapy for tumours deficient in ARID1A. Nat Commun. 2016;7:13837.","journal-title":"Nat Commun"},{"key":"3265_CR16","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1146\/annurev.biochem.73.011303.073723","volume":"73","author":"A Sancar","year":"2004","unstructured":"Sancar A, Lindsey-Boltz LA, Unsal-Kacmaz K, Linn S. Molecular mechanisms of mammalian DNA repair and the DNA damage checkpoints. Annu Rev Biochem. 2004;73:39\u201385.","journal-title":"Annu Rev Biochem"},{"key":"3265_CR17","doi-asserted-by":"crossref","first-page":"905","DOI":"10.3390\/cancers12040905","volume":"12","author":"L Kurz","year":"2020","unstructured":"Kurz L, Miklyaeva A, Skowron MA, Overbeck N, Poschmann G, Becker T, et al. ARID1A Regulates Transcription and the Epigenetic Landscape via POLE and DMAP1 while ARID1A Deficiency or Pharmacological Inhibition Sensitizes Germ Cell Tumor Cells to ATR Inhibition. Cancers (Basel). 2020;12:905.","journal-title":"Cancers (Basel)"},{"key":"3265_CR18","doi-asserted-by":"crossref","first-page":"3195","DOI":"10.1200\/JCO.19.02404","volume":"38","author":"TA Yap","year":"2020","unstructured":"Yap TA, O\u2019Carrigan B, Penney MS, Lim JS, Brown JS, de Miguel Luken MJ, et al. Phase I Trial of First-in-Class ATR Inhibitor M6620 (VX-970) as Monotherapy or in Combination With Carboplatin in Patients With Advanced Solid Tumors. J Clin Oncol. 2020;38:3195\u2013204.","journal-title":"J Clin Oncol"},{"key":"3265_CR19","doi-asserted-by":"crossref","first-page":"1685","DOI":"10.1021\/acschembio.0c00312","volume":"15","author":"EJ Chory","year":"2020","unstructured":"Chory EJ, Kirkland JG, Chang CY, D\u2019Andrea VD, Gourisankar S, Dykhuizen EC, et al. Chemical Inhibitors of a Selective SWI\/SNF Function Synergize with ATR Inhibition in Cancer Cell Killing. ACS Chem Biol. 2020;15:1685\u201396.","journal-title":"ACS Chem Biol"},{"key":"3265_CR20","doi-asserted-by":"crossref","DOI":"10.1093\/narcan\/zcaa005","volume":"2","author":"K Kurashima","year":"2020","unstructured":"Kurashima K, Kashiwagi H, Shimomura I, Suzuki A, Takeshita F, Mazevet M, et al. SMARCA4 deficiency-associated heterochromatin induces intrinsic DNA replication stress and susceptibility to ATR inhibition in lung adenocarcinoma. NAR Cancer. 2020;2:zcaa005.","journal-title":"NAR Cancer"},{"key":"3265_CR21","doi-asserted-by":"crossref","first-page":"1471","DOI":"10.1136\/ijgc-2021-002973","volume":"31","author":"S Banerjee","year":"2021","unstructured":"Banerjee S, Stewart J, Porta N, Toms C, Leary A, Lheureux S, et al. ATARI trial: ATR inhibitor in combination with olaparib in gynecological cancers with ARID1A loss or no loss (ENGOT\/GYN1\/NCRI). Int J Gynecol Cancer. 2021;31:1471\u20135.","journal-title":"Int J Gynecol Cancer"},{"key":"3265_CR22","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1038\/s41571-024-00863-5","volume":"21","author":"NYL Ngoi","year":"2024","unstructured":"Ngoi NYL, Pilie PG, McGrail DJ, Zimmermann M, Schlacher K, Yap TA. Targeting ATR in patients with cancer. Nat Rev Clin Oncol. 2024;21:278\u201393.","journal-title":"Nat Rev Clin Oncol"},{"key":"3265_CR23","doi-asserted-by":"crossref","first-page":"1515","DOI":"10.1016\/j.cell.2015.11.015","volume":"163","author":"T Hart","year":"2015","unstructured":"Hart T, Chandrashekhar M, Aregger M, Steinhart Z, Brown KR, MacLeod G, et al. High-Resolution CRISPR Screens Reveal Fitness Genes and Genotype-Specific Cancer Liabilities. Cell. 2015;163:1515\u201326.","journal-title":"Cell"},{"key":"3265_CR24","doi-asserted-by":"crossref","first-page":"190156","DOI":"10.1098\/rsob.190156","volume":"9","author":"N Hustedt","year":"2019","unstructured":"Hustedt N, Alvarez-Quilon A, McEwan A, Yuan JY, Cho T, Koob L, et al. A consensus set of genetic vulnerabilities to ATR inhibition. Open Biol. 2019;9:190156.","journal-title":"Open Biol"},{"key":"3265_CR25","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1016\/j.molcel.2016.03.006","volume":"62","author":"S Ruiz","year":"2016","unstructured":"Ruiz S, Mayor-Ruiz C, Lafarga V, Murga M, Vega-Sendino M, Ortega S, et al. A Genome-wide CRISPR Screen Identifies CDC25A as a Determinant of Sensitivity to ATR Inhibitors. Mol Cell. 2016;62:307\u201313.","journal-title":"Mol Cell"},{"key":"3265_CR26","doi-asserted-by":"crossref","unstructured":"Qiu Z, Fa P, Liu T, Prasad CB, Ma S, Hong Z et al. A genome-wide pooled shRNA screen identifies PPP2R2A as a predictive biomarker for the response to ATR and CHK1 inhibitors. Cancer Res. 2020;80:3305\u201318.","DOI":"10.1158\/0008-5472.CAN-20-0057"},{"key":"3265_CR27","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1016\/j.trecan.2018.08.003","volume":"4","author":"CJ Ryan","year":"2018","unstructured":"Ryan CJ, Bajrami I, Lord CJ. Synthetic Lethality and Cancer - Penetrance as the Major Barrier. Trends Cancer. 2018;4:671\u201383.","journal-title":"Trends Cancer"},{"key":"3265_CR28","doi-asserted-by":"crossref","first-page":"e268","DOI":"10.1016\/S1470-2045(13)70591-6","volume":"15","author":"R Murali","year":"2014","unstructured":"Murali R, Soslow RA, Weigelt B. Classification of endometrial carcinoma: more than two types. Lancet Oncol. 2014;15:e268\u2013278.","journal-title":"Lancet Oncol"},{"key":"3265_CR29","doi-asserted-by":"crossref","unstructured":"McConechy M, Chen V, Morin G, Brenton J, Huntsman D. PPP2R1A mutations affect PP2A complex formation, and novel protein interactions in gynecological carcinoma cell lines. In: Proceedings of the AACR Special Conference on Advances in Ovarian Cancer Research: From Concept to Clinic. Miami, FL: AACR; 2013.","DOI":"10.1158\/1078-0432.OVCA13-A25"},{"key":"3265_CR30","doi-asserted-by":"crossref","first-page":"4242","DOI":"10.1158\/0008-5472.CAN-19-0218","volume":"79","author":"SE Taylor","year":"2019","unstructured":"Taylor SE, O\u2019Connor CM, Wang Z, Shen G, Song H, Leonard D, et al. The Highly Recurrent PP2A Aalpha-Subunit Mutation P179R Alters Protein Structure and Impairs PP2A Enzyme Function to Promote Endometrial Tumorigenesis. Cancer Res. 2019;79:4242\u201357.","journal-title":"Cancer Res"},{"key":"3265_CR31","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1038\/s41388-019-1012-2","volume":"39","author":"CM O\u2019Connor","year":"2020","unstructured":"O\u2019Connor CM, Leonard D, Wiredja D, Avelar RA, Wang Z, Schlatzer D, et al. Inactivation of PP2A by a recurrent mutation drives resistance to MEK inhibitors. Oncogene. 2020;39:703\u201317.","journal-title":"Oncogene"},{"key":"3265_CR32","doi-asserted-by":"crossref","first-page":"5719","DOI":"10.1158\/0008-5472.CAN-15-3342","volume":"76","author":"D Haesen","year":"2016","unstructured":"Haesen D, Abbasi Asbagh L, Derua R, Hubert A, Schrauwen S, Hoorne Y, et al. Recurrent PPP2R1A Mutations in Uterine Cancer Act through a Dominant-Negative Mechanism to Promote Malignant Cell Growth. Cancer Res. 2016;76:5719\u201331.","journal-title":"Cancer Res"},{"key":"3265_CR33","doi-asserted-by":"crossref","first-page":"1424","DOI":"10.1038\/modpathol.2016.138","volume":"29","author":"M Toda-Ishii","year":"2016","unstructured":"Toda-Ishii M, Akaike K, Suehara Y, Mukaihara K, Kubota D, Kohsaka S, et al. Clinicopathological effects of protein phosphatase 2, regulatory subunit A, alpha mutations in gastrointestinal stromal tumors. Mod Pathol. 2016;29:1424\u201332.","journal-title":"Mod Pathol"},{"key":"3265_CR34","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1038\/s41436-020-00981-2","volume":"23","author":"L Lenaerts","year":"2021","unstructured":"Lenaerts L, Reynhout S, Verbinnen I, Laumonnier F, Toutain A, Bonnet-Brilhault F, et al. The broad phenotypic spectrum of PPP2R1A-related neurodevelopmental disorders correlates with the degree of biochemical dysfunction. Genet Med. 2021;23:352\u201362.","journal-title":"Genet Med"},{"key":"3265_CR35","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1038\/s41586-019-1711-4","volume":"576","author":"AV Anzalone","year":"2019","unstructured":"Anzalone AV, Randolph PB, Davis JR, Sousa AA, Koblan LW, Levy JM, et al. Search-and-replace genome editing without double-strand breaks or donor DNA. Nature. 2019;576:149\u201357.","journal-title":"Nature"},{"key":"3265_CR36","doi-asserted-by":"crossref","first-page":"M110 004317","DOI":"10.1074\/mcp.M110.004317","volume":"10","author":"TM Greco","year":"2011","unstructured":"Greco TM, Yu F, Guise AJ, Cristea IM. Nuclear import of histone deacetylase 5 by requisite nuclear localization signal phosphorylation. Mol Cell Proteomics. 2011;10:M110 004317.","journal-title":"Mol Cell Proteomics"},{"key":"3265_CR37","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1007\/s11010-005-3089-x","volume":"269","author":"S Mitsuhashi","year":"2005","unstructured":"Mitsuhashi S, Shima H, Tanuma N, Sasa S, Onoe K, Ubukata M, et al. Protein phosphatase type 2A, PP2A, is involved in degradation of gp130. Mol Cell Biochem. 2005;269:183\u20137.","journal-title":"Mol Cell Biochem"},{"key":"3265_CR38","doi-asserted-by":"crossref","first-page":"9117","DOI":"10.1074\/jbc.M607563200","volume":"282","author":"DH Lao","year":"2007","unstructured":"Lao DH, Yusoff P, Chandramouli S, Philp RJ, Fong CW, Jackson RA, et al. Direct binding of PP2A to Sprouty2 and phosphorylation changes are a prerequisite for ERK inhibition downstream of fibroblast growth factor receptor stimulation. J Biol Chem. 2007;282:9117\u201326.","journal-title":"J Biol Chem"},{"key":"3265_CR39","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1126\/science.aap9346","volume":"361","author":"JC Saldivar","year":"2018","unstructured":"Saldivar JC, Hamperl S, Bocek MJ, Chung M, Bass TE, Cisneros-Soberanis F, et al. An intrinsic S\/G2 checkpoint enforced by ATR. Science. 2018;361:806\u201310.","journal-title":"Science"},{"key":"3265_CR40","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1101\/gad.452308","volume":"22","author":"LI Toledo","year":"2008","unstructured":"Toledo LI, Murga M, Gutierrez-Martinez P, Soria R, Fernandez-Capetillo O. ATR signaling can drive cells into senescence in the absence of DNA breaks. Genes Dev. 2008;22:297\u2013302.","journal-title":"Genes Dev"},{"key":"3265_CR41","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1038\/ncb2201","volume":"13","author":"C Lukas","year":"2011","unstructured":"Lukas C, Savic V, Bekker-Jensen S, Doil C, Neumann B, Pedersen RS, et al. 53BP1 nuclear bodies form around DNA lesions generated by mitotic transmission of chromosomes under replication stress. Nat Cell Biol. 2011;13:243\u201353.","journal-title":"Nat Cell Biol"},{"key":"3265_CR42","doi-asserted-by":"crossref","first-page":"E5757","DOI":"10.1073\/pnas.1603252113","volume":"113","author":"A Moreno","year":"2016","unstructured":"Moreno A, Carrington JT, Albergante L, Al Mamun M, Haagensen EJ, Komseli ES, et al. Unreplicated DNA remaining from unperturbed S phases passes through mitosis for resolution in daughter cells. Proc Natl Acad Sci USA. 2016;113:E5757\u20135764.","journal-title":"Proc Natl Acad Sci USA"},{"key":"3265_CR43","doi-asserted-by":"crossref","first-page":"e0264138","DOI":"10.1371\/journal.pone.0264138","volume":"17","author":"CA Milbury","year":"2022","unstructured":"Milbury CA, Creeden J, Yip WK, Smith DL, Pattani V, Maxwell K, et al. Clinical and analytical validation of FoundationOne(R)CDx, a comprehensive genomic profiling assay for solid tumors. PLoS One. 2022;17:e0264138.","journal-title":"PLoS One"},{"key":"3265_CR44","doi-asserted-by":"crossref","first-page":"3407","DOI":"10.1016\/j.celrep.2016.12.031","volume":"17","author":"K Sanjiv","year":"2016","unstructured":"Sanjiv K, Hagenkort A, Calderon-Montano JM, Koolmeister T, Reaper PM, Mortusewicz O, et al. Cancer-Specific Synthetic Lethality between ATR and CHK1 Kinase Activities. Cell Rep. 2016;17:3407\u201316.","journal-title":"Cell Rep"},{"key":"3265_CR45","doi-asserted-by":"crossref","first-page":"1629","DOI":"10.1016\/j.celrep.2013.04.002","volume":"3","author":"SV Srinivasan","year":"2013","unstructured":"Srinivasan SV, Dominguez-Sola D, Wang LC, Hyrien O, Gautier J. Cdc45 is a critical effector of myc-dependent DNA replication stress. Cell Rep. 2013;3:1629\u201339.","journal-title":"Cell Rep"},{"key":"3265_CR46","doi-asserted-by":"crossref","first-page":"972","DOI":"10.1158\/2159-8290.CD-14-0943","volume":"5","author":"F Cottini","year":"2015","unstructured":"Cottini F, Hideshima T, Suzuki R, Tai YT, Bianchini G, Richardson PG, et al. Synthetic Lethal Approaches Exploiting DNA Damage in Aggressive Myeloma. Cancer Discov. 2015;5:972\u201387.","journal-title":"Cancer Discov"},{"key":"3265_CR47","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1038\/nature05953","volume":"448","author":"D Dominguez-Sola","year":"2007","unstructured":"Dominguez-Sola D, Ying CY, Grandori C, Ruggiero L, Chen B, Li M, et al. Non-transcriptional control of DNA replication by c-Myc. Nature. 2007;448:445\u201351.","journal-title":"Nature"},{"key":"3265_CR48","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1016\/j.molcel.2020.10.008","volume":"80","author":"F Li","year":"2020","unstructured":"Li F, Kozono D, Deraska P, Branigan T, Dunn C, Zheng XF, et al. CHK1 Inhibitor Blocks Phosphorylation of FAM122A and Promotes Replication Stress. Mol Cell. 2020;80:410\u201322 e416.","journal-title":"Mol Cell"},{"key":"3265_CR49","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1038\/nbt.2800","volume":"32","author":"H Koike-Yusa","year":"2014","unstructured":"Koike-Yusa H, Li Y, Tan EP, Velasco-Herrera MDC, Yusa K. Genome-wide recessive genetic screening in mammalian cells with a lentiviral CRISPR-guide RNA library. Nat Biotechnol. 2014;32:267\u201373.","journal-title":"Nat Biotechnol"},{"key":"3265_CR50","doi-asserted-by":"crossref","first-page":"3962","DOI":"10.1158\/0008-5472.CAN-21-4339","volume":"82","author":"MJ Llorca-Cardenosa","year":"2022","unstructured":"Llorca-Cardenosa MJ, Aronson LI, Krastev DB, Nieminuszczy J, Alexander J, Song F, et al. SMG8\/SMG9 Heterodimer Loss Modulates SMG1 Kinase to Drive ATR Inhibitor Resistance. Cancer Res. 2022;82:3962\u201373.","journal-title":"Cancer Res"},{"key":"3265_CR51","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1038\/nmeth.3901","volume":"13","author":"S Tyanova","year":"2016","unstructured":"Tyanova S, Temu T, Sinitcyn P, Carlson A, Hein MY, Geiger T, et al. The Perseus computational platform for comprehensive analysis of (prote)omics data. Nat Methods. 2016;13:731\u201340.","journal-title":"Nat Methods"},{"key":"3265_CR52","doi-asserted-by":"crossref","first-page":"3854","DOI":"10.3390\/cancers13153854","volume":"13","author":"S Khalique","year":"2021","unstructured":"Khalique S, Nash S, Mansfield D, Wampfler J, Attygale A, Vroobel K, et al. Quantitative Assessment and Prognostic Associations of the Immune Landscape in Ovarian Clear Cell Carcinoma. Cancers. 2021;13:3854.","journal-title":"Cancers"}],"container-title":["Oncogene"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41388-024-03265-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41388-024-03265-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41388-024-03265-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,24]],"date-time":"2025-02-24T05:04:22Z","timestamp":1740373462000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41388-024-03265-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,12]]},"references-count":52,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2025,3,17]]}},"alternative-id":["3265"],"URL":"https:\/\/doi.org\/10.1038\/s41388-024-03265-0","relation":{},"ISSN":["0950-9232","1476-5594"],"issn-type":[{"value":"0950-9232","type":"print"},{"value":"1476-5594","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,12]]},"assertion":[{"value":"17 June 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 December 2024","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 December 2024","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 February 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"CJL makes the following disclosures: receives and\/or has received research funding from: AstraZeneca, Merck KGaA, Artios, Neophore. Received consultancy, SAB membership or honoraria payments from: FoRx, Syncona, Sun Pharma, Gerson Lehrman Group, Merck KGaA, Vertex, AstraZeneca, Tango Therapeutics, 3rd Rock, Ono Pharma, Artios, Abingworth, Tesselate, Dark Blue Therapeutics, Pontifax, Astex, Neophore, Glaxo Smith Kline, Dawn Bioventures, Blacksmith Medicines, FoRx Therapeutics, Ariceum. Has stock in: Tango, Ovibio, Hysplex, Tesselate. CJL is also a named inventor on patents describing the use of DNA repair inhibitors and stands to gain from their development and use as part of the ICR \u201cRewards to Inventors\u201d scheme and also reports benefits from this scheme associated with patents for PARP inhibitors paid into CJL\u2019s personal account and research accounts at the Institute of Cancer Research. SB makes the following disclosure: receives and\/or has received research funding from: AstraZeneca. Received consultancy, SAB membership or honoraria payments from Abbvie, Astrazeneca, Biontech, Eisai, Gilead, GlaxoSmithKline, Grey Wolf Therapeutics, Immunogen, Incyte, ITM Oncologics, Merck Sharpe Dohme, Mersana, Myriad, Oncxerna, Pharmaand, Seagen, Takeda. Verastem, Zymeworks.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}